Robust generation of hemangioblastic progenitors from human embryonic stem cells

Regenerative Medicine
Shi-Jiang LuRobert Lanza

Abstract

Human embryonic stem cells (hESCs) are a potentially inexhaustible source of cells for replacement therapy. However, successful preclinical and clinical progress requires efficient and controlled differentiation towards the specific differentiated cell fate. We previously developed a strategy to generate blast cells (BCs) from hESCs that were capable of differentiating into vascular structures as well as into all hematopoietic cell lineages. Although the BCs were shown to repair damaged vasculature in multiple animal models, the large-scale generation of cells under these conditions was challenging. Here we report a simpler and more efficient method for robust generation of hemangioblastic progenitors. In addition to eliminating several expensive factors that are unnecessary, we demonstrate that bone morphogenetic protein (BMP)-4 and VEGF are necessary and sufficient to induce hemangioblastic commitment and development from hESCs during early stages of differentiation. BMP-4 and VEGF significantly upregulate T-brachyury, KDR, CD31 and Lmo2 gene expression, while dramatically downregulating Oct-4 expression. The addition of basic FGF during growth and expansion was found to further enhance BC development, consistently generating...Continue Reading

References

Feb 1, 1995·Cellular and Molecular Neurobiology·E Terasawa
Sep 1, 1996·The Journal of General Virology·I AfrikanovaO Burrone
Feb 27, 1999·Experimental Cell Research·M V Wiles, B M Johansson
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Aug 2, 2003·Circulation Research·Patrizia Dell'EraMarco Presta
Apr 28, 2004·Developmental Biology·Irene GinisMahendra S Rao
Feb 3, 2005·Nature Medicine·Maria J MartinAjit Varki
Nov 1, 2005·Nature Biotechnology·Kevin A D'AmourEmmanuel E Baetge
Nov 12, 2005·Stem Cells·Mark E LevensteinJames A Thomson
Jan 3, 2006·Nature Biotechnology·Tenneille E LudwigJames A Thomson
Jul 25, 2006·Nature Methods·Tenneille E LudwigJames A Thomson
May 9, 2007·Nature Methods·Shi-Jiang LuRobert Lanza

❮ Previous
Next ❯

Citations

Mar 26, 2011·Stem Cells International·Erin A Kimbrel, Shi-Jiang Lu
Apr 19, 2012·Experimental Hematology·Melanie D Kardel, Connie J Eaves
Mar 6, 2015·Journal of Cellular Biochemistry·Tong ChenZack Z Wang
Mar 11, 2015·Stem Cells International·Zhijing LiuChengshi Quan
Jul 10, 2016·Tissue Engineering. Part C, Methods·Jaichandran SivalingamSteve Kah-Weng Oh
Sep 1, 2009·Experimental Cell Research·Saswati Banerjee, Methode Bacanamwo
May 16, 2018·BMC Hematology·Maria Teresa Esposito
Apr 21, 2019·International Journal of Molecular Sciences·Ahmed Abdal DayemAnd Ssang-Goo Cho
Mar 4, 2011·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Nian Cao, Zhong-Xiang Yao
Apr 24, 2019·Nature Biomedical Engineering·Haodong ChenJoseph C Wu
Jan 29, 2020·Bioactive Materials·Yuqian Jiang, Xiaojun Lance Lian

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

GraphPad Prism
MxPro
GraphPad

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Cell Fate Conversion By mRNA

mRNA-based technology is being studied as a potential technology that could be used to reprogram cell fate. This technique provides the potential to generate safe reprogrammed cells that can be used for clinical applications. Here is the latest research on cell fate conversion by mRNA.